Edition:
United States

Cyclopharm Ltd (CYC.AX)

CYC.AX on Australia Stock Exchange

0.90AUD
29 May 2017
Change (% chg)

$0.03 (+3.45%)
Prev Close
$0.87
Open
$0.90
Day's High
$0.90
Day's Low
$0.90
Volume
3,374
Avg. Vol
39,822
52-wk High
$1.46
52-wk Low
$0.67

Latest Key Developments (Source: Significant Developments)

Cyclopharm appoints David Heaney as chairman
Tuesday, 28 Mar 2017 05:49pm EDT 

Cyclopharm Ltd :Appoints David Heaney as chairman of company's board.  Full Article

Cyclopharm expects FY16 underlying EBITDA of about $3.4 mln
Sunday, 5 Feb 2017 06:54pm EST 

Cyclopharm Ltd : Confirms it remains on track to record initial sales of ultralutetm in first half of 2017 .Expects to report record sales revenue for 2016 full year of $14.4 million and underlying EBITDA of approximately $3.4 million.  Full Article

Cyclopharm Ltd receives special protocol assessment agreement1 from FDA
Tuesday, 22 Nov 2016 09:34pm EST 

Cyclopharm Ltd : Received special protocol assessment (spa ) agreement1 from United States Food And Drug Administration . Received special protocol assessment agreement1 for patient trials of its technegas product, to be known as cyc‐009 .Approval process remains on track for completion by mid‐2018 at a cost of less than $7 million usd.  Full Article

Cyclopharm signs agreement with Canadian Association Of Nuclear Medicine
Sunday, 26 Jun 2016 10:10pm EDT 

Cyclopharm Ltd : signs agreement with the Canadian Association Of Nuclear Medicine .  Full Article

Cyclopharm Ltd says Technegas order received from China
Monday, 20 Jun 2016 11:52pm EDT 

Cyclopharm Ltd : Trading update & record technegas order received from China . First half 2016 revenues are expected to be up 21% versus pcp to just over $6.1 million" . Says gross margins for first half 2016 are expected to increase approximately 28% as compared to the same prior year . Says Cyclopharm has received order for its technegas generators . Order received by Cyclopharm from Chinese distributor has approximate value of aud$1.3 million .  Full Article

Jubilant Life Sciences' unit, Cyclopharm terminate term sheet for Technegas licensing agreement
Wednesday, 11 May 2016 07:18am EDT 

Jubilant Life Sciences Ltd : Jubilant and Cyclopharm mutually agree to terminate term sheet for technegas licensing agreement . Both parties have agreed to discuss potential commercial opportunities once CYC obtains USFDA approval for Technegas .  Full Article

Cyclopharm says not to proceed to binding agreement with Jubilant Draximage
Tuesday, 10 May 2016 03:29am EDT 

Cyclopharm Ltd : Cyclopharm to proceed independently with FDA trials . Not to proceed to binding agreement with Jubilant Draximage . Says trial program remains on track, targeting USFDA approval in mid-2018 . Total cost to Cyclopharm is expected to be less than US$7 million .  Full Article

Cyclopharm Limited to pay ordinary dividend
Wednesday, 26 Aug 2015 11:04pm EDT 

Cyclopharm Limited:Says ordinary fully paid dividend of A$0.11000000 per share.Payment date is on Oct 14.Record date is on Oct 7.  Full Article

More From Around the Web

BRIEF-Cyclopharm appoints David Heaney as chairman

* Appoints David Heaney as chairman of company's board Source text for Eikon: Further company coverage:

No consensus analysis data available.